Concepedia

Kate Van Brunt

KV

Statistics

Publications

12

Citations

429

H-Index

11

Active since

2010

Affiliations

Eli Lilly (United States)(Current)

Eli Lilly (United Kingdom)

Vertex Pharmaceuticals (United States)

Eli Lilly (Canada)

Health Outcomes Solutions (United States)

Kate Van Brunt is an author at Eli Lilly (United States) specializing in diabetes, medicine, and patient-reported outcomes.

Top concepts

Publications per year

2010–2023

12

Publications

12

Utilities and disutilities for attributes of injectable treatments for type 2 diabetes

Kristina S. Boye, Louis S. Matza, Kimberly N. Walter et al. · The European Journal of Health Economics · 2010 · 138 citations

, , +5

Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes

Glenn Matfin, Kate Van Brunt, Alan G. Zimmermann et al. · Journal of Diabetes Science and Technology · 2015 · 49 citations · Full text

EFFECT OF ELEXACAFTOR/TEZACAFTOR/IVACAFTOR ON ANNUAL RATE OF LUNG FUNCTION DECLINE IN PEOPLE WITH CYSTIC FIBROSIS

Tim Lee, Gregory S. Sawicki, Josje Altenburg et al. · Journal of Cystic Fibrosis · 2022 · 49 citations · Full text

Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor

Isabelle Fajac, Cori Daines, I. Durieu et al. · Journal of Cystic Fibrosis · 2022 · 36 citations · Full text

Health state utilities for skeletal-related events secondary to bone metastases

Louis S. Matza, Karen Chung, Kate Van Brunt et al. · The European Journal of Health Economics · 2013 · 31 citations · Full text

1–5 of 12